Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

ABSTRACT:

SUBMITTER: Sangro B 

PROVIDER: S-EPMC12282661 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature